Skip to content

US · BCTX · BIOTECHNOLOGY

BriaCell Therapeutics Corp. (BCTX) intrinsic value and stock valuation

$3.06as of 2026-11-21 · Mkt cap 6.59M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

BriaCell Therapeutics Corp. DCF and intrinsic value

InvestorsCraft values BCTX with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from BCTX’s statements →

BriaCell Therapeutics Corp. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology West Vancouver, BC V7T 2X1 briacell.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$0.00
20112025
Net income
-$-36.49M
20112025
Free cash flow
-$-39.07M
20112025
Total equity
$23.8M
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-37.73M-$-33.34M-$-31.08M-$-19.61M-$-8.72M
Net income-$-36.49M-$-4.79M-$-27.11M-$-34.42M-$-17.27M
EPSd-$-19.41M-$-4.35M-$-26.07M-$-33.42M-$-57.57M
Operating cash flow-$-39.07M-$-32.97M-$-31.89M-$-15.87M-$-9.89M
Capital expenditure$0.00-$-620K$0.00$0.00-$0.00
Free cash flow-$-39.07M-$-33.59M-$-31.89M-$-15.87M-$-9.89M
Total assets$29.8M$8.15M$36.3M$54.6M$72.5M
Total debt$0.00$0.00$0.00$0.00$30K
Net debt-$-14.43M-$-1.2M-$-28.38M-$-52.63M-$-71.54M
Total equity$23.8M-$-3.73M-$-5.04M$13.3M$34.6M
Cash and short-term investments$24.6M$1.2M$28.4M$52.6M$71.6M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$150K$80K$20K$20K$20K
Gross profit-$-150K-$-80K-$-20K-$-20K-$-20K
Research and development expenses$29.5M$27.2M$20.5M$10.3M$2.53M
Selling, general and administrative expenses$8.08M$6.15M$10.6M$9.32M$6.19M
Other expenses$0.00$0.00$0.00$0.00-$0.00
Operating expenses$37.6M$33.3M$31.1M$19.6M$8.72M
Cost and expenses$37.7M$33.3M$31.1M$19.6M$8.72M
Interest income$170K$280K$1.2M$170K$0.00
Interest expense$50K$0.00$0.00$0.00$100K
Depreciation and amortization$150K$80K$20K$20K$20K
Ebitda-$-37.58M-$-4.85M-$-31.06M-$-34.4M-$-17.15M
Operating income-$-37.73M-$-33.34M-$-31.08M-$-19.61M-$-8.72M
Total other income/expenses, net$900K$28.4M$3.97M-$-14.81M-$-8.55M
Income before tax-$-36.83M-$-4.93M-$-27.11M-$-34.42M-$-17.27M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-36.49M-$-4.79M-$-27.11M-$-34.42M-$-17.27M
Weighted average shares outstanding$1.88M$1.1M$1.04M$1.03M$300K
Weighted average diluted shares outstanding$1.88M$1.1M$1.04M$1.03M$300K
Balance sheet
20252024202320222021
Cash and short-term investments$24.6M$1.2M$28.4M$52.6M$71.6M
Net receivables$780K$1.9M$960K$30K$20K
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$27.4M$5.07M$36M$54.3M$72.2M
Property, plant and equipment, net$410K$540K$0.00$0.00$0.00
Goodwill and intangible assets$250K$280K$290K$300K$310K
Long-term investments$720K$580K$0.00$0.00$0.00
Total non-current assets$2.37M$3.08M$290K$300K$310K
Total assets$29.8M$8.15M$36.3M$54.6M$72.5M
Accounts payable$4.51M$9.95M$1.5M$590K$270K
Short-term debt$0.00$0.00$0.00$0.00$0.00
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$5.47M$10.4M$2.41M$1.21M$700K
Long-term debt$0.00$0.00$0.00$0.00$30K
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$460K$1.52M$38.9M$40.2M$37.3M
Capital lease obligations$0.00$0.00$0.00$0.00$0.00
Total liabilities$5.93M$11.9M$41.3M$41.4M$38M
Common stock$139.9M$100.2M$92.9M$84.1M$68.5M
Retained earnings-$-153.65M-$-118.61M-$-107.71M-$-77.4M-$-36.42M
Accumulated other comprehensive income (loss)$38.4M-$-190K-$-190K-$-180K-$-170K
Total equity$23.8M-$-3.73M-$-5.04M$13.3M$34.6M
Total investments$10.9M$580K$0.00$0.00$0.00
Total debt$0.00$0.00$0.00$0.00$30K
Net debt-$-14.43M-$-1.2M-$-28.38M-$-52.63M-$-71.54M
Cash flow statement
20252024202320222021
Net income-$-36.5M-$-6.55M-$-27.27M-$-34.13M-$-17.63M
Depreciation and amortization$150K$110K$20K$20K$20K
Stock-based compensation$0.00$0.00$0.00$0.00$0.00
Change in working capital-$-2.65M$9.64M-$-4.74M-$-500K-$-2.91M
Accounts receivable$1.02M-$-1M$10K-$-10K$10K
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable-$-5.39M$0.00$0.00$0.00$0.00
Net cash provided by operating activities-$-39.07M-$-32.97M-$-31.89M-$-15.87M-$-9.89M
Investments in property, plant and equipment$0.00-$-620K$0.00$0.00$0.00
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-10.61M-$-930K$0.00$0.00$0.00
Common stock issued$63M$6.04M$5.37M$8.2M$83.3M
Common stock repurchased$0.00$0.00-$-60K-$-12.93M$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$63M$6.04M$5.31M-$-4.76M$82.9M
Net change in cash$13.2M-$-28.23M-$-26.25M-$-20.77M$71.6M
Cash at end of period$14.4M$1.2M$28M$52.7M$71.6M
Operating cash flow-$-39.07M-$-32.97M-$-31.89M-$-15.87M-$-9.89M
Capital expenditure$0.00-$-620K$0.00$0.00-$0.00
Free cash flow-$-39.07M-$-33.59M-$-31.89M-$-15.87M-$-9.89M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About BriaCell Therapeutics Corp.

        BriaCell Therapeutics Corp. is an immuno-oncology biotechnology company primarily focused on developing innovative immunotherapies to combat cancer. The firm's leading experimental drug, Bria-IMT, is currently undergoing Phase I/IIa clinical investigation. This crucial study evaluates its effectiveness when utilized in conjunction with immune checkpoint inhibitors for treating breast cancer. Beyond its flagship program, BriaCell has forged a collaborative research and development partnership with the National Cancer Institute (NCI). This alliance is dedicated to progressing Bria-OTS, a personalized immunotherapy designed for advanced breast cancer patients, and BriaDx, a proprietary diagnostic assay. The company's main offices are situated in West Vancouver, Canada.

        CEO
        William V. Williams
        Employees
        16
        Beta
        1.52

        Explore

        Frequently asked questions

        What is the intrinsic value of BriaCell Therapeutics Corp. (BCTX)?

        InvestorsCraft does not currently publish an intrinsic value for BCTX. How the IC value is calculated.

        Is BCTX undervalued?

        InvestorsCraft does not publish an undervaluation signal for BCTX at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.